Metis Phase 3 Clinical Trial Demonstrates Significant Progress in Delaying Brain Metastasis with Improved Quality of Life, as Novocure Releases Promising Data at ASCO 2024
ROOT, Switzerland - Novocure (NASDAQ: NVCR) has made a groundbreaking announcement during the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The company revealed the results of its phase 3 METIS clinical trial, which focused on the use of Tumor Treating Fields (TTFields) therapy in the treatment of brain metastases from non-small cell lung cancer (NSCLC). These results have showcased significant improvements in delaying time to intracranial progression, along with enhanced quality of life deterioration-free survival.
The METIS trial enlisted 298 adult patients with 1-10 brain metastases from NSCLC. Novocure conducted a randomized phase 3 clinical trial, comparing stereotactic radiosurgery with or without TTFields therapy for these patients. The promising findings from this trial will be presented at the prestigious ASCO Annual Meeting, highlighting the immense potential of this innovative treatment approach.
TTFields therapy has been an instrumental part of treating newly diagnosed glioblastoma (GBM) for almost a decade. Novocure also announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial, which evaluates the safety and efficacy of initiating Optune Gio (formerly known as Optune) concurrently with radiation therapy and temozolomide (TMZ) for adult patients with newly diagnosed GBM. Novocure’s commitment to pushing the boundaries of medical advancements is evident through their relentless pursuit of improved treatment options for a range of cancers.
The results of the METIS trial are highly significant, as brain metastases pose significant challenges and severely impact the prognosis of NSCLC patients. By efficiently delaying the time to intracranial progression, Novocure’s TTFields therapy offers hope to those affected by NSCLC and brain metastases. Furthermore, improved quality of life deterioration-free survival is an essential aspect of cancer treatment, ensuring patients can maintain a better quality of life throughout their journey.
Novocure’s innovative approach to cancer treatment has consistently demonstrated its potential in clinical trials. The METIS trial’s positive outcome is yet another testament to the company’s commitment to revolutionizing patient care. By combining various therapeutic approaches, Novocure continues to lead the way in transforming the landscape of cancer treatment.
In conclusion, Novocure’s phase 3 METIS trial has yielded impressive results in delaying brain metastasis in NSCLC patients while improving quality of life. This development is a significant breakthrough in the treatment of NSCLC, and it highlights Novocure’s determination to make a tangible difference in the lives of cancer patients. As the scientific community eagerly awaits the presentation of these encouraging results at ASCO 2024, it is evident that Novocure’s TTFields therapy is a game-changer in the fight against cancer.
Comments